The use of immunocytochemical study in the cytologic diagnosis of melanoma: Evaluation of three antibodies by Jing, Xin et al.
The Use of Immunocytochemical
Study in the Cytologic Diagnosis
of Melanoma:
Evaluation of Three Antibodies
Xin Jing, M.D.,1* Claire W. Michael, M.D.,1
and Constantine G.A. Theoharis, M.D.2
There are limited studies on the utility of immunostaining in
cytologic specimens suspected of melanoma. In this study, we
examined the performance of the most commonly used antibod-
ies including monoclonal antibodies against Melan-A (A103),
S-100, and HMB-45 antigens. Immunostains were performed on
formalin-fixed, paraffin-embedded cell blocks prepared from
100 cytologic specimens. The specimens consisted of 57 mela-
nomas and 43 nonmelanocytic neoplasms. Of 57 melanomas,
53 showed positive reaction to Melan-A antibody while 51 and
41 revealed positive immunostaining for S-100 and HMB-45,
respectively. Of 43 nonmelanocytic neoplasms, 10, 4, and 8
specimens stained positive with an antibody against S-100,
HMB-45, and Melan-A, respectively. However, the false-posi-
tive immunostaining for Melan-A was eliminated in seven of
the eight specimens after applying the pretreatment with avi-
din/biotin blocking reagents. Overall, the highest sensitivity
and negative predictive value (NPV) were achieved in Melan-A
antibody (93 and 90%) compared with antibodies to S-100 (89
and 85%), and HMB-45 (72 and 71%). Initially, an intermedi-
ate specificity and positive predictive value (PPV) were
obtained for Melan-A antibody (81 and 87%) that were greater
than S-100 (77 and 84%), and lower than HMB-45 (91 and
91%). However, the aforementioned treatment with avidin/bio-
tin blocking reagents improved both specificity (98%) and PPV
(98%) for Melan-A antibody. In conclusion, by blocking endog-
enous biotin, Melan-A antibody offers the greatest perform-
ance. In terms of cost-effectiveness, we suggested that Melan-A
antibody should be used as the first-line antibody for detecting
melanoma in the cytologic specimens. Diagn. Cytopathol.
2013;41:126–130. ' 2011 Wiley Periodicals, Inc.
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Malignant melanoma is notorious for its great variety of
cytohistomorphological features which may be seen in
almost any nonmelanocytic malignant neoplasm and
rarely non-neoplastic/benign conditions. Cytologically,
melanoma cells may present as dispersed, single cells
pattern or in discohesive clusters. Occasionally, it may
present as large cohesive or papillary-like groups. The
majority of melanoma cells are polygonal or plasmacytoid
shaped with eccentric, hyperchromatic nuclei, as well as
occasional reddish prominent nucleoli and intranuclear
inclusions. However, it is not uncommon to see other cell
types including spindle cells, lymphoma-like small round
cells, and undifferentiated/anaplastic cells. The latter are
often large, pleomorphic cells with bi- or multinuclea-
tion.1,2 Thus, immunostaining has been extensively used
under the following circumstances: (1) confirmation of
recurrent melanoma which shows unusual morpholologi-
cal features; (2) work-up of differential diagnoses in a
patient who has known history of more than one malig-
nant neoplasm including melanoma; and (3) establishment
of diagnosis for a neoplasm of unknown origin.
Melan-A/MART-1 gene was identified as a gene encod-
ing a melanocyte lineage-specific antigen that is recognized
by autologous cytotoxic lymphocytes.3,4 Ohsie et al. under-
took a literature review on immunohistochemical studies
with Melan-A/MART-1 antibody that were performed on
paraffin-embedded histologic specimens. Accordingly,
Melan-A/MART-1 antibody has demonstrated a sensitivity
ranging from 75 to 92% and a specificity ranging from
95 to 100% in detecting melanoma.5 There are limited stud-
ies regarding the utilization of Melan-A/MART-1 antibody
in cytologic materials.6–8 In this study, we assessed our
experience with sensitivity, specificity, positive (PPV), and
negative (NPV) predictive value of Melan-A monoclonal
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antibody (A103) for detecting melanoma in cytologic
specimens, in comparison with antibodies to S-100 and
HMB-45.
Materials and Methods
A SNOMED search of the electronic pathology database
in our institution for the last 10-year period retrieved a
total of 150 cases with an established diagnosis of mela-
noma or its mimics. Upon assessing the original hematox-
ylin and eosin-stained cell block slides prepared from the
individual cases, 50 cases were excluded from the study
due to the absence or the presence of scant cells of inter-
est. The study employed remaining 100 cases consisting
of 57 melanomas and 43 nonmelanocytic neoplasms
that need to be considered in the differential diagnosis
(Table I). The specimens of melanoma were prepared
from 54 fine-needle aspirates (FNAs) and three effusions.
The sources of nonmelanocytic neoplasms were 35 FNAs
and 8 effusions.
Immunostaining was performed on paraffin-embedded
cell blocks. Briefly, 4-lm sections were cut, mounted on
positively charged PLUS2 slides (Baxter cat#M6146-
PLUS) and heated at 608C for 30–60 min. Using the
standard avidin-biotin-peroxidase complex technique,
immunostaining was performed on the Ventana ES auto-
mated immunohistochemistry system and the Ventana
DAB detection kit (Ventana Medical Systems, Tucson,
AZ). Antibodies used for immunostaining (Dako Corpora-
tion, Carpinteria, CA) were Melan-A (A103), S-100, and
HMB-45. Dilutions and methods of pretreatment for the
individual antibodies are shown in Table II. Appropriate
positive and negative controls were obtained.
All cases were reviewed blindly and the immunostain-
ing was assessed based on the approximate percentage of
neoplastic cells showing positive cytoplasmic staining
(Melan A and HMB-45) or positive nuclear/cytoplasmic
staining (S-100) and scored as follows: 0 (complete lack
of or blush staining), 1 (5–25%), 2 (25–50%), 3 (50–
75%), and 4 (75–100%). The immunostaining was consid-
ered to be positive when a score of 1 or greater was
obtained. Using the established cytologic and/or histologic
diagnosis as the gold standard, sensitivity, and specificity,
as well as PPV and NPV were calculated.
Results
Among the 57 melanoma specimens, six specimens
stained positive for only one of the three markers, includ-
ing three for Melan-A and three for S-100 while none of
the specimens show positive staining for HMB-45 alone;
11 specimens stained positive for two markers, including
nine for Melan-A and S-100 and two for Melan-A and
HMB-45; and the remaining 39 specimens showed posi-
tive staining for all three markers. Table III summarizes
immunostaining reactions to antibodies against Melan-A,
S-100, and HMB-45. Of the 57 specimens of melanoma,
53 revealed positive reactions (a score of 1 or greater)
with immunostaining for Melan-A while 51 and 41 speci-
mens showed positive immunostaining for S-100 and
HMB-45, respectively (Fig. 1). None of the antibodies
produced a positive reaction in more than 75% (an immu-
nostaining score of 4) of melanoma cells. However, posi-
tive immunostaing with a score of 3 (50–75% cells
stained) was observed in a greater number of melanoma
specimens for Melan-A (n ¼ 27) compared with S-100
(n ¼ 15) and HMB-45 (n ¼ 20). Of the 43 nonmelano-
cytic specimens, positive immunostaining for Melan-A
was observed in eight specimens (seven FNAs and one
effusion), including rhabdomyosarcoma 1, adenocarci-
noma of the breast origin 2 (including one pleural
effusion), leiomyosarcoma 1, lymphoma 1, hepatocellular
carcinoma 2, and renal cell carcinoma 1. The majority
Table I. Nonmelanocytic Neoplasms
Source of specimen Number of specimen
Poorly differentiated squamous cell carcinoma 3
Small cell carcinoma of lung 2
Breast carcinoma 6
Renal cell carcinoma 5
Hepatocellular carcinoma 3




Spindle cell neoplasm 1
Germ cell neoplasm 1
Table II. Description of the Antibodies
Antibody Dilution Pretreatment
Melan-A 1:12.5 Tris-EDTA at PH 9.0,
microwaved for 15 min
S-100 1:500 None
HMB-45 1:25 Protease
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of the nonmelanocytic specimens with a false-positive
reaction for Melan-A antibody exhibited an immunostain-
ing scores 1 or 2 while a score of 3 was seen in one
hepatocellular carcinoma and 1 breast adenocarcinoma. In
contrast to the crisp, well-defined staining pattern in mela-
noma, nonmelanocytic specimens showed low intensity,
faint staining. While repeating immunostaining for Melan-
A in these eight specimens with false-positive reaction
after the specimens were pretreated using avidin/biotin
blocking reagents prior to the immunostaining procedure,
the false-positive reaction with Melan-A antibody was
eliminated in seven specimens (an example shown in
Fig. 2). Positive immunostaining for S-100 and HMB-45
was also observed with a score of 1 in 10 and 4 nonmela-
nocytic neoplasms, respectively.
The highest sensitivity and negative predictive value
(NPV) were achieved in Melan-A antibody (93 and 90%)
compared with antibodies to S-100 (89 and 85%), and
HMB-45 (72 and 71%). Initially, an intermediate specific-
ity and positive predictive value (PPV) were obtained
for Melan-A antibody (81 and 87%) that were greater
Fig. 1. Positive immunostaining for (A) Melan A, (B) S-100, (C) HMB-45
in the melanoma specimen (immunostain, 4003). [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
Fig. 2. A: The cell block material prepared from effusion of metastatic
breast carcinoma showed false-positive immunostaining for Melan A. B:
The false-positive staining was eliminated upon applying pretreatment
with avidin/biotin blocking reagents (immunostain, 4003). [Color figure
can be viewed in the online issue, which is available at wileyonline
library.com.]
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than S-100 (77 and 84%), and lower than HMB-45
(91 and 91%). However, the aforementioned treatment
with avidin/biotin blocking reagents improved both speci-
ficity (98%) and PPV (98%) for Melan-A antibody.
Discussion
As mentioned previously, immunostaining plays a very
vital role in order to confirm recurrent melanoma, work
up of differential diagnoses and establish diagnosis for a
neoplasm of unknown origin. The most commonly used
melanocytic markers include S-100 and HMB 45 proteins.
S-100 belongs to a calcium binding group of proteins.
S-100 protein is considered a sensitive but not a specific
melanocytic marker due to the fact that it presents in not
only high proportion of melanomas, but also nonmelano-
cytic neoplasms such as gliomas, Schwannomas, and neu-
rofibromas.9 On the other hand, HMB-45, a cytoplasmic
premelanosomal glycoprotein is considered a more
specific but less sensitive melanocytic marker compared
with S-100.
MART-1/Melan-A antigen is a marker of melanosomal
differentiation that is recognized by autologous cytotoxic
lymphocytes.3,4 MART-1/Melan-A is a relatively newer
melanocytic marker and two clones of antibody are avail-
able: MART-1 (M2-7C10) and Melan-A (A103).10
According to the literature review on immunohistochemi-
cal studies by Ohsie et al., Melan-A/MART-1 antibody
demonstrated a sensitivity ranging from 75 to 92% and a
specificity ranging from 95 to 100% in detecting mela-
noma while sensitivity and specificity of S-100 ranged
from 97 to 100% and 75–87%, respectively; HMB-45
showed a sensitivity of 69–93% and a specificity of 56–
100%.5
There are a few studies comparing the performance of
MART-1/Melan-A, S-100m and HMB-45 in cytology
specimens. In this regard, MART-1 was reported as a
potentially preferable antibody over HMB-45 for the diag-
nosis of metastatic melanoma using cytospin preparation
of FNAs.8 While testing immunostainig on melanoma
cells of effusions (mainly cell block and a few cytospin
preparations), MART-1 antibody showed the rate of
positive staining (78%) which was compatible with that
of S-100 or HMB-45 (81%).6 A study consisting of cell
blocks prepared from 40 melanoma (mainly FNAs) and
32 nonmelanocytic neoplasms demonstrated that in com-
parison with S-100 and HMB-45, Melan-A has the great-
est sensitivity (95%) and NPV (94%). Both specificity
(97%) and PPV (97%) of Melan-A are compatible with
that of HMB-45, which were greater than that of S-100.7
In this study, immunostaining was performed on the
cell blocks which were prepared predominantly from
FNAs. Similar to the previously reported data, Melan-A
also demonstrated the greatest sensitivity (93%) and NPV
(90%). Initially, an intermediate specificity and positive
predictive value (PPV) were obtained for Melan-A anti-
body (81 and 87%) that were relatively lower than the
aforementioned data.7 The relatively lower specificity and
PPV for Melan-A is thought to be associated with the
false-positive immunostaining for Melan-A seen in 8 non-
melanocytic neoplasms. The false-positive staining was
caused by retrieved endogenous biotin, a product of the
heating procedure, which is a known factor causing
pitfalls in immunostaining.11 However, applying the pre-
treatment with avidin/biotin blocking reagents eliminated
the false-positive reaction with Melan-A antibody in
seven cases and therefore improved both specificity (98%)
and PPV (98%) for Melan-A antibody. It has been
reported that false-positive reaction resulting from endog-
enous biotin can be effectively avoided by utilization
of newer, nonavidin-biotin polymer-based methods.12,13
Currently, immunostaining for Melan-A is performed in
our laboratory using the biotin-free method.
It is noteworthy to mention that a few specimens of
melanoma group in the current study showed positivity
staining for Melan-A or S-100 only (n ¼ 3 each). On the
other hand, none of the melanoma specimens reacted with
the antibody against HMB-45 alone.
In an effort to continue to explore the most cost-effec-
tive approach of utilization of ancillary tests as a comple-
ment in the cytologic diagnosis of melanoma, identifica-
tion of the optimal panel of stains is desired. On the basis
of our results and the results of other studies, Melan-A
can be used by itself and S-100 can be used subsequently
when Melan-A is not informative. HMB-45 seldom adds
additional information.
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